An Open‐Label Randomized Controlled Non‐Inferiority Trial of Arginine Glutamate Injection for the Treatment of Mild Hepatic Encephalopathy

Both regimens effectively alleviated mild HE symptoms and reduced ammonia levels. Arginine glutamate showed non-inferiority to LOLA in terms of clinical improvement, ammonia reduction, and time to complete NCT-A, with no significant adverse events.